Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Fuji
Cipla
Baxter
Farmers Insurance
Julphar
QuintilesIMS
Accenture
Colorcon

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,250,419

« Back to Dashboard

Summary for Patent: 7,250,419
Title:Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
Inventor(s): Hardern; David (Sutton Bonington, GB), Ingall; Anthony (Loughborough, GB), Springthorpe; Brian (Loughborough, GB), Willis; Paul (West Bridgford, GB), Guile; Simon (Loughborough, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:11/230,493
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,250,419
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,250,419

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF MYOCARDIAL INFARCTION ➤ Try a Free Trial
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME ➤ Try a Free Trial
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF STABLE AND UNSTABLE ANGINA ➤ Try a Free Trial
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y METHOD OF INHIBITING PLATELET AGGREGATION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,250,419

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE46276 Triazolo(4,5-D)pyrimidine compounds ➤ Try a Free Trial
6,525,060 Triazolo(4,5-d)pyrimidine compounds ➤ Try a Free Trial
6,974,868 Compounds ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,250,419

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 023920 ➤ Try a Free Trial
Argentina 058967 ➤ Try a Free Trial
Argentina 072756 ➤ Try a Free Trial
Austria 261970 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
QuintilesIMS
US Department of Justice
Mallinckrodt
Teva
Dow
Fuji
Express Scripts
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.